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Abstract
Background: Sales data indicate a major increase in the prescription of antifungal drugs in the last
two decades. Many new agents for systemic use that only recently have become available are likely
to be prescribed intensively in acute care hospitals. Sales data do not adequately describe the
developments of drug use density. Given the concerns about the potential emergence of antifungal
drug resistance, data on drug use density, however, may be valuable and are needed for analyses of
the relationship between drug use and antifungal resistance.
Methods: Hospital pharmacy records for the years 2001 to 2003 were evaluated, and the number
of prescribed daily doses (PDD, defined according to locally used doses) per 100 patient days were
calculated to compare systemic antifungal drug use density in different medical and surgical service
areas between five state university hospitals.
Results: The 3-year averages in recent antifungal drug use for the five hospitals ranged between
8.6 and 29.3 PDD/100 patient days in the medical services (including subspecialties and intensive
care), and between 1.1 and 4.0 PDD/100 patient days in the surgical services, respectively. In all five
hospitals, systemic antifungal drug use was higher in the hematology-oncology service areas (mean,
48.4, range, 24 to 101 PDD/100 patient days, data for the year 2003) than in the medical intensive
care units (mean, 18.3, range, 10 to 33 PDD/100) or in the surgical intensive care units (mean, 10.7,
range, 6 to 18 PDD/100). Fluconazole was the most prescribed antifungal drug in all areas. In 2003,
amphotericin B consumption had declined to 3 PDD/100 in the hematology-oncology areas while
voriconazole use had increased to 10 PDD/100 in 2003.
Conclusion:  Hematology-oncology services are intense antifungal drug prescribing areas.
Fluconazole and other azol antifungal drugs are the most prescribed drugs in all patient care areas
while amphotericin B use has considerably decreased. The data may be useful as a benchmark for
focused interventions to improve prescribing quality.
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Background
There has been a major increase in the prescription of
antifungal drugs after the introduction of fluconazole into
the market in the late 1980s, and again in the late 1990s.
The systemic antifungal market has continued to experi-
ence growth since 1999, increasing in value from $2.1 bil-
lion to $3.3 billion in 2003. The azoles dominate the
systemic antifungal market, accounting for 52% of total
sales in 2003 [1-8]. The reasons for the increasing antifun-
gal drug use are manifold. Among hospitalized patients,
the empiric use of antifungals in both hematology-oncol-
ogy as well as intensive care patients is now common.
Often, treatment is initiated based on preliminary micro-
biology results, and definite diagnosis of invasive infec-
tion versus colonization may be difficult [4,9-11]. New
antifungal drugs such as itraconazole, caspofungin, and
voriconazole have become available and broadened ther-
apeutic options [12]. In some settings an increasing inci-
dence of invasive fungal infections and the emergence of
infections due to rare and atypical organisms has been
observed, and this changing epidemiology has contrib-
uted to more intense use of antifungal drugs [13]. In the
ambulatory care setting there was a shift from prescribing
intravaginal antifungal preparations to fluconazole over-
the-counter, raising concern about the possible develop-
ment of azole drug resistance [14-16].
Although multiple current and projected market and sales
data on systemic antifungal drugs are available, few stud-
ies have provided estimates of antifungal drug use density
especially in hospitals. Alvarez-Lerma and colleagues
reported a prescription rate of 14% in intensive care unit
patients [9]. In a survey we conducted in 1994 the pre-
scription prevalence rate in hospitalized patients was
10.2% per patient-week in the medical service and 3.5%
per patient-week in the surgical services [17]. Hospital
expenditures were also evaluated in some studies. How-
ever, we were unable to find information on recent hospi-
tal antifungal drug utilization that uses the daily doses per
100 patient days format which is now common in phar-
macoepidemiologic surveys. We therefore collected data
from the pharmacies of five university hospitals and here
report overall and comparative use density values for
defined patient care areas.
Methods
Pharmacy data on systemic antifungal drug use in the
medical and surgical services of five university hospitals
located across Germany were obtained for the period
2001 to 2003. The five university hospitals included, here
designated A through E, varied in size from ~1,000 to
~1,700 beds, and differed from each other in structure,
special services offered, and in the availability of interde-
partmental guidelines and an antiinfective therapeutics
committee, drug formularies, formulary restrictions, and
infectious disease consultation services.
We used a consensus definition of (usually) prescribed
daily doses (PDD) in adults (Table 1) according to local
guidelines. This definition differs from the daily doses
defined by the WHO/ATC classification http://
www.whocc.no which defines lower doses for amphoter-
icin B, fluconazole, and itraconazole (Table 2). Antifungal
drug use density was calculated as yearly PDD/100 patient
days (i.e. occupied bed days). Separate data were calcu-
lated for the medical ICU (MICU), the surgical ICU
(SICU), and the hematology-oncology services, respec-
tively. We also calculated yearly means of overall and spe-
cific antifungal use densities to assess time trends.
Results and discussion
The yearly antifungal drug use densities differed between
the five hospitals in particular for the medical services.
Hospital A showed use density values of consistently >20
PDD/100 patient days while hospital E values were con-
sistently <10 PDD/100 patient days (Figure 1). Less
variation between the hospitals were observed in the sur-
gical services (Figure 1). Here, 3-year averages for the hos-
pitals ranged between 1.1 (hospital A) and 4.0 PDD/100
patient days (hospital B), respectively.
Time trend
Overall, the mean antifungal drug use for the five hospi-
tals increased between the years 2001 and 2003 from 12.4
to 15.4 PDD/100 patient days in the medical services
(+24%), but only from 2.1 to 2.2 PDD/100 patient days
in the surgical services (+5%). Applying the WHO/ATC
definition of daily defined doses (DDD; including our
daily dose definition for liposomal amphotericin B), cor-
responding values for the years 2001 and 2003 were cal-
culated to be 22.8 to 26.3 DDD/100 patient days (+15%)
in the medical services, and 4 to 4.1 DDD/100 patient
Table 1: Definitions of prescribed daily doses (PDD) and WHO/
ATC defined daily doses (DDD) for systemic antifungal drugs.
PDD DDD
amphotericin B deoxycholate* 50 mg 35 mg
liposomal amphotericin B 250 mg nd#
flucytosin 10 g 10 g
ketoconazole 400 mg 400 mg
fluconazole 400 mg 200 mg
itraconazole 400 mg 200 mg
voriconazole 400 mg 400 mg
caspofungin 50 mg 50 mg
*conventional amphotericin B
#not definedBMC Clinical Pharmacology 2005, 5:1 http://www.biomedcentral.com/1472-6904/5/1
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days (+4%) in the surgical services, respectively (data not
shown).
Use of specific antifungal drugs
As in other reports [5], fluconazole was the most fre-
quently prescribed antifungal drug in the medical as well
as surgical services of the five hospitals. Its use did not
decrease over time. Figure 2 shows the yearly mean use
density for fluconazole and other antifungal drugs (except
the rarely used 5-flucytosin and ketoconazole) in the
medical service. Interestingly, conventional as well as
liposomal amphotericin B use decreased over time (Figure
2). In the year 2003, the mean use of fluconazole in the
medical service was 7.7 PDD/100 patient days
(representing 50% of all PDDs), and 1.8 PDD/100 patient
days in the surgical service (representing 78% of all
PDDs), respectively.
Differences between patient care areas
As expected, antifungal drug use was much more intense
in the hematology-oncology services and intensive care
areas (Figure 3) than in general internal medicine (mean
use, 2.3 PDD/100 patient days, data for the year 2003)
and general surgery (mean use, 1.1 PDD/100 patient days,
data for the year 2003). Figure 3 shows that there was
some variation between the hospitals in the use density
values, particularly in hematology-oncology and the SICU
area. These differences were not explained by different
Yearly systemic antifungal drug use density in the medical and surgical services of five university hospitals (A through E) for the  years 2001–2002–2003 Figure 1
Yearly systemic antifungal drug use density in the medical and surgical services of five university hospitals (A through E) for the 
years 2001–2002–2003.
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Use density for different antifungal drugs in the medical serv-
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incidences of invasive fungal infections as perceived by
the local physicians, but in none of the hospitals specific
surveillance for fungal infections was activated. Large
differences were also noted in the fluconazole use, with
very high use density values in hospital A hematology-
oncology and comparatively low density values in hospi-
tal E hematology-oncology areas (53.8 versus 5.8 PDD/
100 patient days, data for the year 2003). The high use
density values in hospital A hematology-oncology could
primarily be explained by the heavy use of relatively high
doses of fluconazole (400 mg daily) for prophylactic pur-
poses which was much less common in the other
hospitals.
Of note, hospital E had a moderately active infectious dis-
ease consultant service with an antimicrobial agents man-
agement program, and this was previously associated with
low antibacterial drug use in the medical service [18,19].
According to the present study, this programme was also
perhaps linked to the low antifungal drug use density in
the hospital E medical service including hematology-
oncology.
In hospital C, there was a program in the MICU attempt-
ing to decrease the use of fluconazole based solely on pos-
itive cultures for yeasts in tracheal or bronchial secretions.
This program, which was primarily a focused infectious
Use of fluconazole (grey bars) versus other systemic antifungal drugs (black bars) in the SICU, MICU, and in the hematology- oncology services of five university hospitals (A through E) during the years 2001–2002–2003 Figure 3
Use of fluconazole (grey bars) versus other systemic antifungal drugs (black bars) in the SICU, MICU, and in the hematology-
oncology services of five university hospitals (A through E) during the years 2001–2002–2003.
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diseases consultation program was started in 2002, and
appeared to be effective in decreasing fluconazole use
from 13.5 to 5 PDD/100 patient days without changing
the use density of other systemic antifungal drugs (Figure
3).
The decreasing use of amphotericin B consumption seen
in the medical service was to a large part explained by
decreasing use of the drug in the hematology-oncology
wards. Mean use density values changed between 2001
and 2003 from 5.8 to 2.4 PDD/100 patient days for con-
ventional amphotericin B, and from 1.6 to 0.6 for lipo-
somal amphotericin B, respectively. These changes were
associated with increasing values for voriconazole in
hematology-oncology. This new drug after its introduc-
tion into the market in 2002 increased from zero to a use
density of 10.3 PDD/100 patient days in 2003. Interest-
ingly. 80% of all doses of voriconazole in hematology-
oncology were by the oral route.
Limitations and conclusions
Our study was not designed to evaluate appropriateness
of antifungal drug therapy. Few studies in the hospital set-
ting have addressed this issue. In two previous studies, it
was found that dosages of fluconazole were not always
adequate [20,21]. In another study, therapy was consid-
ered "unconventional" in 27% of the courses and 41% of
the regimens, mainly because either the indication or the
duration of treatment did not conform to conventional
practice [4]. Conventional practice, however, can differ
considerably as indicated by our results. We think it is
unlikely that the observed high use density values in
hospital A hematology-oncology (>50 PDD/100 patient
days) represents an unusual epidemiologic situation or a
major difference in hematology-oncology patient-mix.
Rather, the intense use can be explained by liberal anti-
fungal drug use in high doses for prophylaxis and perhaps
empiric combination therapy. The present study, thus,
provided a useful benchmark suggesting that more
detailed analysis of antifungal therapy indication practice
is warranted in this particular hospital.
In summary, this report describes the range of antifungal
drug use in certain patient care areas of large tertiary-care
teaching hospitals in Germany. Consistent with other
reports, we found that fluconazole has remained the most
frequently prescribed drug in this setting.
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